Genome-Wide/NN
Association/NN
Study/NN
of/IN
Metabolic/JJ
Syndrome/NN
in/IN
Koreans/NNS
./.
====================
Metabolic/JJ
syndrome/NN
(/(
METS/NNS
)/)
is/VBZ
a/DT
disorder/NN
of/IN
energy/NN
utilization/NN
and/CC
storage/NN
and/CC
increases/VBZ
the/DT
risk/NN
of/IN
developing/VBG
cardiovascular/JJ
disease/NN
and/CC
diabetes/VBZ
./.
====================
To/TO
identify/VB
the/DT
genetic/JJ
risk/NN
factors/NNS
of/IN
METS/NNS
,/,
we/PRP
carried/VBD
out/RP
a/DT
genome-wide/JJ
association/NN
study/NN
(/(
GWAS/NN
)/)
for/IN
2,657/CD
cases/NNS
and/CC
5,917/CD
controls/NNS
in/IN
Korean/JJ
populations/NNS
./.
====================
As/IN
a/DT
result/NN
,/,
we/PRP
could/MD
identify/VB
2/CD
single/JJ
nucleotide/NN
polymorphisms/NNS
(/(
SNPs/NNS
)/)
with/IN
genome-wide/JJ
significance/NN
level/NN
p-values/NNS
(/(
</JJR
5/CD
×/NN
10-8/CD
)/)
,/,
8/CD
SNPs/NNS
with/IN
genome-wide/JJ
suggestive/JJ
p-values/NNS
(/(
5/CD
×/NN
10-8/CD
≤/NNP
p/NN
</JJR
1/CD
×/NN
10-5/CD
)/)
,/,
and/CC
2/CD
SNPs/NNS
of/IN
more/RBR
functional/JJ
variants/NNS
with/IN
borderline/JJ
p-values/NNS
(/(
5/CD
×/NN
10-5/CD
≤/NNP
p/NN
</JJR
1/CD
×/NN
10-4/CD
)/)
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
the/DT
multiple/JJ
correction/NN
criteria/NNS
of/IN
conventional/JJ
GWASs/NNS
exclude/VBP
false-positive/JJ
loci/NNS
,/,
but/CC
simultaneously/RB
,/,
they/PRP
discard/VBP
many/JJ
true-positive/JJ
loci/NNS
./.
====================
To/TO
reconsider/VB
the/DT
discarded/JJ
true-positive/JJ
loci/NNS
,/,
we/PRP
attempted/VBD
to/TO
include/VB
the/DT
functional/JJ
variants/NNS
(/(
nonsynonymous/JJ
SNPs/NNS
[/(
nsSNPs/NNS
]/)
and/CC
expression/NN
quantitative/JJ
trait/NN
loci/NNS
[/(
eQTL/NN
]/)
)/)
among/IN
the/DT
top/NN
5,000/CD
SNPs/NNS
based/VBN
on/IN
the/DT
proportion/NN
of/IN
phenotypic/JJ
variance/NN
explained/VBN
by/IN
genotypic/JJ
variance/NN
./.
====================
In/IN
total/JJ
,/,
159/CD
eQTLs/NNS
and/CC
18/CD
nsSNPs/NNS
were/VBD
presented/VBN
in/IN
the/DT
top/NN
5,000/CD
SNPs/NNS
./.
====================
Although/IN
they/PRP
should/MD
be/VB
replicated/VBN
in/IN
other/JJ
independent/JJ
populations/NNS
,/,
6/CD
eQTLs/NNS
and/CC
2/CD
nsSNP/NN
loci/NNS
were/VBD
located/JJ
in/IN
the/DT
molecular/JJ
pathways/NNS
of/IN
LPL/NN
,/,
APOA5/NN
,/,
and/CC
CHRM2/NN
,/,
which/WDT
were/VBD
the/DT
significant/JJ
or/CC
suggestive/JJ
loci/NNS
in/IN
the/DT
METS/NNS
GWAS/NN
./.
====================
Conclusively/RB
,/,
our/PRP$
approach/NN
using/VBG
the/DT
conventional/JJ
GWAS/NN
,/,
reconsidering/VBG
functional/JJ
variants/NNS
and/CC
pathway-based/JJ
interpretation/NN
,/,
suggests/VBZ
a/DT
useful/JJ
method/NN
to/TO
understand/VB
the/DT
GWAS/NN
results/NNS
of/IN
complex/NN
traits/VBZ
and/CC
can/MD
be/VB
expanded/VBN
in/IN
other/JJ
genomewide/JJ
association/NN
studies/NNS
./.
====================
Metabolic/JJ
syndrome/NN
(/(
METS/NNS
)/)
is/VBZ
a/DT
disorder/NN
of/IN
energy/NN
utilization/NN
and/CC
storage/NN
and/CC
increases/VBZ
the/DT
risk/NN
of/IN
developing/VBG
cardiovascular/JJ
disease/NN
and/CC
diabetes/VBZ
./.
====================
METS/NNS
includes/VBZ
multiple/JJ
clinical/JJ
traits/NNS
,/,
as/IN
follows/VBZ
:/:
increased/VBD
plasma/NN
glucose/NN
,/,
abdominal/JJ
obesity/NN
,/,
dyslipidemia/NN
,/,
and/CC
high/JJ
blood/NN
pressure/NN
[/(
1/CD
]/)
./.
====================
METS/NNS
is/VBZ
a/DT
great/JJ
concern/NN
in/IN
developing/VBG
countries/NNS
,/,
because/IN
the/DT
prevalence/NN
of/IN
METS/NNS
is/VBZ
gradually/RB
increasing/VBG
,/,
especially/RB
in/IN
countries/NNS
where/WRB
it/PRP
follows/VBZ
obesity/NN
trends/VBZ
,/,
sedentary/JJ
lifestyle/JJ
,/,
and/CC
high/JJ
consumption/NN
of/IN
calories/NNS
[/(
2/CD
,/,
3/CD
,/,
4/CD
]/)
./.
====================
A/DT
Korean/JJ
twin/NN
study/NN
showed/VBD
that/IN
the/DT
METS/NNS
has/VBZ
51/CD
%/NN
-60/CD
%/NN
heritability/NN
,/,
indicating/VBG
a/DT
significant/JJ
role/NN
of/IN
genetic/JJ
factors/NNS
in/IN
the/DT
development/NN
of/IN
METS/NNS
[/(
5/CD
]/)
./.
====================
Therefore/RB
,/,
understanding/VBG
the/DT
genetic/JJ
factors/NNS
underlying/VBG
the/DT
syndrome/NN
and/CC
their/PRP$
correlation/NN
is/VBZ
clinically/RB
important/JJ
./.
====================
Recent/JJ
advances/NNS
in/IN
high-throughput/JJ
genomics/NNS
technologies/NNS
have/VBP
allowed/VBN
massive/JJ
testing/NN
of/IN
genetic/JJ
variants/NNS
in/IN
minimal/JJ
time/NN
[/(
6/CD
,/,
7/CD
]/)
./.
====================
The/DT
reductions/NNS
in/IN
cost/JJ
and/CC
time/NN
have/VBP
made/VBN
it/PRP
feasible/JJ
to/TO
conduct/VB
large-scale/JJ
genome-wide/NN
association/NN
studies/NNS
(/(
GWASs/NNS
)/)
that/WDT
genotype/NN
many/JJ
thousands/NNS
of/IN
single/JJ
nucleotide/NN
polymorphisms/NNS
(/(
SNPs/NNS
)/)
in/IN
thousands/NNS
of/IN
individuals/NNS
./.
====================
So/RB
far/RB
,/,
approximately/RB
1,900/CD
reports/NNS
with/IN
13,000/CD
SNPs/NNS
(/(
GWAS/NN
catalog/NN
;/:
Apr/NNP
14/CD
,/,
2014/CD
)/)
have/VBP
been/VBN
published/VBN
to/TO
identify/VB
the/DT
gene-disease/NN
or/CC
-non-disease/JJ
trait/VBP
associations/NNS
./.
====================
The/DT
quantitative/JJ
traits/VBZ
related/JJ
to/TO
METS/NNS
have/VBP
already/RB
been/VBN
studied/VBN
by/IN
the/DT
conventional/JJ
GWAS/NN
in/IN
the/DT
Korean/JJ
population/NN
[/(
8/CD
]/)
,/,
but/CC
there/EX
is/VBZ
no/DT
Korean/JJ
GWAS/NN
report/VBP
about/IN
METS/NNS
cases/NNS
and/CC
controls/VBZ
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
relatively/RB
little/JJ
trait/VBP
heritability/NN
can/MD
be/VB
explained/VBN
by/IN
the/DT
conventional/JJ
GWAS/NN
[/(
9/CD
]/)
./.
====================
These/DT
phenomena/NNS
,/,
called/VBN
missing/VBG
heritability/NN
problems/VBZ
,/,
are/VBP
hard/RB
to/TO
solve/VB
by/IN
conventional/JJ
GWAS/NN
,/,
in/IN
part/NN
because/IN
of/IN
the/DT
extensive/JJ
multiple/JJ
testing/VBG
correction/NN
in/IN
GWAS/NN
analysis/NN
,/,
low/JJ
effect/NN
size/NN
of/IN
common/JJ
variants/NNS
,/,
and/CC
the/DT
difficulty/NN
of/IN
detecting/VBG
low-frequency/NN
or/CC
rare/JJ
variants/NNS
in/IN
conventional/JJ
GWAS/NN
./.
====================
Multiple/JJ
testing/NN
correction/NN
is/VBZ
necessary/JJ
to/TO
exclude/VB
false-positive/JJ
loci/NNS
,/,
but/CC
simultaneously/RB
,/,
it/PRP
discards/VBZ
many/JJ
true-positive/JJ
loci/NNS
[/(
10/CD
]/)
./.
====================
Also/RB
,/,
most/JJS
SNPs/NNS
in/IN
these/DT
GWASs/NNS
lie/VBP
in/IN
intergenic/JJ
and/CC
intron/NN
regions/NNS
and/CC
do/VBP
not/RB
appear/VB
to/TO
affect/VB
protein/NN
sequence/NN
./.
====================
Thus/RB
,/,
these/DT
SNPs/NNS
are/VBP
likely/JJ
functionally/RB
neutral/JJ
or/CC
just/RB
proxies/NNS
of/IN
causal/JJ
variants/NNS
located/JJ
in/IN
the/DT
same/JJ
linkage/NN
disequilibrium/NN
(/(
LD/NN
)/)
./.
====================
To/TO
understand/VB
the/DT
amount/NN
of/IN
true-positive/JJ
signals/NNS
in/IN
the/DT
discarded/JJ
association/NN
results/VBZ
,/,
we/PRP
computed/VBD
the/DT
proportion/NN
[/(
V/JJ
(/(
G/NN
)/)
/V/NN
(/(
P/NN
)/)
]/)
of/IN
the/DT
phenotypic/JJ
variance/NN
[/(
V/JJ
(/(
P/NN
)/)
]/)
that/IN
is/VBZ
explained/VBN
by/IN
the/DT
genotype/NN
variance/NN
[/(
V/JJ
(/(
G/NN
)/)
]/)
using/VBG
the/DT
significant/JJ
and/CC
discarded/VBD
SNP/NN
results/VBZ
[/(
11/CD
]/)
./.
====================
Recently/RB
,/,
Fransen/NN
et/FW
al/JJ
./.
====================
[/(
10/CD
]/)
reported/VBD
a/DT
GWAS/JJ
using/VBG
expression/NN
quantitative/JJ
trait/NN
loci/NNS
(/(
eQTL/NN
)/)
information/NN
./.
====================
They/PRP
selected/VBN
eQTL/NN
among/IN
the/DT
GWAS/NN
results/NNS
for/IN
Crohn/NN
's/POS
disease/NN
and/CC
conducted/VBD
follow-up/JJ
replication/NN
studies/NNS
[/(
10/CD
]/)
./.
====================
They/PRP
showed/VBD
that/IN
eQTL-based/VBD
pre-selection/NN
for/IN
follow-up/JJ
is/VBZ
a/DT
useful/JJ
approach/NN
for/IN
identifying/VBG
risk/NN
loci/NNS
from/IN
a/DT
moderately/RB
sized/VBN
GWAS/NN
./.
====================
Based/VBN
on/IN
previous/JJ
knowledge/NN
,/,
we/PRP
applied/VBD
an/DT
alternative/JJ
analysis/NN
strategy/NN
to/TO
understand/VB
the/DT
genetic/JJ
components/NNS
of/IN
METS/NNS
./.
====================
First/RB
of/IN
all/DT
,/,
we/PRP
conducted/VBD
a/DT
conventional/JJ
GWAS/NN
for/IN
METS/NNS
cases/NNS
and/CC
healthy/JJ
controls/NNS
to/TO
discover/JJ
the/DT
top/NN
significant/JJ
signals/NNS
./.
====================
Thereafter/RB
,/,
we/PRP
tried/VBD
to/TO
uncover/JJ
the/DT
functional/JJ
variants/NNS
,/,
such/JJ
as/IN
nonsynonymous/JJ
SNPs/NNS
(/(
nsSNPs/NNS
)/)
and/CC
eQTLs/NNS
,/,
among/IN
the/DT
SNPs/NNS
to/TO
be/VB
discarded/VBN
using/VBG
the/DT
stringent/JJ
criteria/NNS
of/IN
the/DT
conventional/JJ
GWAS/NN
./.
====================
Finally/RB
,/,
we/PRP
drew/VBP
a/DT
pathway/NN
of/IN
the/DT
significantly/RB
associated/VBN
GWAS/NN
SNPs/NNS
and/CC
the/DT
remaining/VBG
less/RBR
significantly/RB
associated/VBN
functional/JJ
SNPs/NNS
./.
====================
The/DT
overall/JJ
study/NN
design/NN
is/VBZ
schematically/RB
described/VBN
in/IN
Supplementary/JJ
Fig/NN
./.
====================
1/CD
./.
====================
Study/NN
subjects/NNS
====================
The/DT
study/NN
subjects/NNS
were/VBD
originally/RB
derived/VBN
from/IN
a/DT
part/NN
of/IN
the/DT
Korean/JJ
Genome/NN
and/CC
Epidemiology/JJ
Study/NN
(/(
KoGES/NN
)/)
project/VBP
,/,
which/WDT
was/VBD
the/DT
national/JJ
project/VB
to/TO
establish/VB
genome/NN
epidemiology/NN
cohorts/NNS
of/IN
Korean/JJ
dwellers/NNS
or/CC
immigrants/emigrants/NNS
[/(
12/CD
]/)
./.
====================
Among/IN
the/DT
KoGES/NN
cohorts/NNS
,/,
the/DT
Korean/JJ
Association/NN
Resource/NN
Consortium/NN
(/(
KARE/NN
)/)
has/VBZ
established/VBN
a/DT
public/JJ
GWAS/NN
dataset/NN
by/IN
using/VBG
the/DT
Ansan-Anseong/JJ
cohort/NN
,/,
which/WDT
is/VBZ
an/DT
ongoing/JJ
biennially/RB
followed-up/JJ
cohort/NN
in/IN
the/DT
KoGES/NN
[/(
13/CD
]/)
./.
====================
The/DT
KARE/NN
dataset/NN
consists/VBZ
of/IN
the/DT
individual/JJ
SNP/NN
chip/NN
genotypes/NNS
and/CC
the/DT
epidemiological/clinical/JJ
phenotypes/NNS
for/IN
studying/VBG
the/DT
genetic/JJ
components/NNS
of/IN
Korean/JJ
public/JJ
health/NN
./.
====================
Written/RB
informed/VBN
consent/NN
was/VBD
obtained/VBN
from/IN
all/DT
participants/NNS
at/IN
the/DT
KoGES/NN
,/,
and/CC
this/DT
research/NN
project/VB
was/VBD
approved/VBN
by/IN
the/DT
Institutional/JJ
Review/NN
Board/JJ
of/IN
Korea/NN
National/JJ
Institute/JJ
of/IN
Health/NN
(/(
KNIH/NN
)/)
./.
====================
The/DT
obtained/VBN
KARE/NN
dataset/NN
passed/VBN
the/DT
quality/NN
control/NN
criteria/NNS
and/CC
was/VBD
reported/VBN
in/IN
previous/JJ
GWAS/NN
reports/NNS
[/(
8/CD
,/,
13/CD
]/)
./.
====================
Briefly/RB
,/,
the/DT
subjects/NNS
with/IN
genotype/NN
accuracies/VBZ
below/IN
98/CD
%/NN
and/CC
high/JJ
missing/VBG
genotype/NN
call/JJ
rates/NNS
(/(
≥5/CD
%/NN
)/)
,/,
high/JJ
heterozygosity/NN
(/(
>/JJR
30/CD
%/NN
)/)
,/,
or/CC
inconsistency/NN
in/IN
sex/NN
were/VBD
excluded/VBN
from/IN
subsequent/JJ
analysis/NN
./.
====================
Individuals/NNS
who/WP
had/VBD
a/DT
tumor/NN
were/VBD
excluded/VBN
,/,
as/IN
were/VBD
related/JJ
individuals/NNS
whose/WP$
estimated/VBN
identity-by-state/VBP
values/NNS
were/VBD
high/JJ
(/(
>/JJR
0.80/CD
)/)
./.
====================
Based/VBN
on/IN
these/DT
criteria/NNS
,/,
8,842/CD
samples/NNS
were/VBD
selected/VBN
;/:
these/DT
quality/NN
control/NN
steps/NNS
have/VBP
been/VBN
described/VBN
in/IN
a/DT
previous/JJ
GWAS/NN
[/(
13/CD
]/)
./.
====================
Study/NN
phenotypes/NNS
and/CC
covariates/VBZ
====================
We/PRP
used/VBD
the/DT
general/JJ
information/NN
on/IN
resident/JJ
areas/NNS
(/(
Anseong/JJ
or/CC
Ansan/JJ
)/)
,/,
sex/NN
,/,
and/CC
age/NN
as/IN
the/DT
covariates/NNS
and/CC
past/NN
disease/NN
history/JJ
of/IN
diabetes/NNS
,/,
hypertension/NN
,/,
and/CC
lipidemia/NN
as/IN
exclusion/NN
criteria/NNS
for/IN
non-METS/JJ
healthy/JJ
controls/NNS
./.
====================
The/DT
height/JJ
and/CC
body/NN
weight/NN
were/VBD
used/VBN
to/TO
calculate/JJ
the/DT
body/NN
mass/NN
index/NN
(/(
BMI/NNP
)/)
as/IN
another/DT
covariate/JJ
,/,
and/CC
waist/NN
circumference/RB
(/(
WC/NN
)/)
,/,
systolic/JJ
and/CC
diastolic/JJ
blood/NN
pressures/NNS
(/(
SBP/NN
and/CC
DBP/NN
)/)
,/,
fasting/VBG
plasma/NN
glucose/NN
levels/NNS
(/(
GLU0/NN
)/)
,/,
high-density/JJ
lipoprotein/NN
(/(
HDL/NN
)/)
cholesterol/NN
,/,
and/CC
triglyceride/NN
(/(
TG/NN
)/)
were/VBD
used/VBN
to/TO
diagnose/VB
METS/NNS
./.
====================
METS/NNS
was/VBD
defined/VBN
by/IN
the/DT
presence/NN
of/IN
three/CD
or/CC
more/RBR
of/IN
the/DT
following/VBG
five/CD
components/NNS
according/VBG
to/TO
the/DT
NCEP-ATPIII/NN
criteria/NNS
using/VBG
WC/NN
for/IN
Asians/JJ
[/(
14/CD
,/,
15/CD
]/)
:/:
WC/NNP
(/(
≥90/CD
cm/RB
for/IN
men/NNS
and/CC
≥80/CD
cm/RB
for/IN
women/NNS
)/)
,/,
HDL/NN
(/(
</JJR
40/CD
mg/dL/NN
for/IN
men/NNS
,/,
</JJR
50/CD
mg/dL/NN
for/IN
women/NNS
)/)
,/,
TG/NN
(/(
≥150/CD
mg/dL/NN
)/)
,/,
SBP/NN
(/(
≥130/CD
mm/NN
Hg/NNP
)/)
and/or/CC
DBP/NN
(/(
≥85/CD
mm/NN
Hg/NNP
)/)
,/,
and/CC
GLU0/NN
(/(
≥100/CD
mg/dL/NN
)/)
./.
====================
Study/NN
genotypes/NNS
====================
The/DT
genotyping/JJ
of/IN
the/DT
cohort/NN
population/NN
was/VBD
previously/RB
described/VBN
for/IN
the/DT
KARE/NN
study/NN
[/(
16/CD
]/)
./.
====================
Most/JJS
DNA/NN
samples/NNS
were/VBD
isolated/VBN
from/IN
the/DT
peripheral/JJ
blood/NN
of/IN
participants/NNS
and/CC
genotyped/VBD
using/VBG
Affymetrix/JJ
Genomewide/NN
Human/JJ
SNP/NN
array/NN
5.0/CD
(/(
Affymetrix/JJ
,/,
Inc./NNP
,/,
Santa/NN
Clara/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
./.
====================
The/DT
quality/NN
control/NN
steps/NNS
of/IN
the/DT
genotypes/NNS
have/VBP
been/VBN
described/VBN
elsewhere/VBP
[/(
13/CD
]/)
./.
====================
Briefly/RB
,/,
the/DT
calling/JJ
of/IN
the/DT
genotyping/VBG
was/VBD
determined/VBN
by/IN
Bayesian/JJ
Robust/NNP
Linear/JJ
Modeling/JJ
using/VBG
the/DT
Mahalanobis/NN
Distance/NN
genotyping/VBG
algorithm/NN
[/(
17/CD
]/)
./.
====================
Consequently/RB
,/,
352,227/CD
SNPs/NNS
had/VBD
a/DT
missing/JJ
genotype/NN
call/JJ
rate/NN
below/IN
0.1/CD
,/,
a/DT
minor/JJ
allele/NN
frequency/NN
greater/JJR
than/IN
0.01/CD
,/,
and/CC
no/DT
deviation/NN
from/IN
Hardy-Weinberg/JJ
equilibrium/NN
(/(
p/NN
>/JJR
1/CD
×/NN
10-6/CD
)/)
./.
====================
Additionally/RB
,/,
the/DT
previous/JJ
GWAS/NN
reported/VBD
no/DT
population/NN
stratification/NN
between/IN
the/DT
Anseong/JJ
and/CC
Ansan/NN
cohorts/NNS
[/(
13/CD
]/)
./.
====================
Statistical/JJ
analysis/NN
====================
The/DT
GWAS/NN
for/IN
METS/NNS
cases/NNS
and/CC
controls/VBZ
was/VBD
conducted/VBN
by/IN
logistic/JJ
regression/NN
analysis/NN
,/,
adjusting/VBG
for/IN
residential/JJ
area/NN
,/,
sex/NN
,/,
age/NN
,/,
and/CC
BMI/NN
as/IN
covariates/VBZ
,/,
implemented/VBD
in/IN
PLINK/NN
version/NN
1.07/CD
[/(
18/CD
]/)
./.
====================
The/DT
significant/JJ
associations/NNS
were/VBD
defined/VBN
by/IN
genomewide/NN
significance/NN
level/NN
p-values/NNS
(/(
</JJR
5/CD
×/NN
10-8/CD
)/)
and/CC
genome-wide/NN
suggestive/JJ
p-values/NNS
(/(
5/CD
×/NN
10-8/CD
≤/CD
p/NN
</JJR
1/CD
×/NN
10-5/CD
)/)
./.
====================
The/DT
LD/NN
between/IN
the/DT
previously/RB
reported/VBD
GWAS/NN
SNPs/NNS
and/CC
the/DT
SNPs/NNS
of/IN
the/DT
current/JJ
GWAS/NN
was/VBD
investigated/VBN
with/IN
SNAP/NN
web-based/VBD
software/RB
(/(
http/NN
:/:
//www.broadinstitute.org/mpg/snap/JJ
)/)
and/CC
GWAS/NN
catalog/NN
(/(
http/NN
:/:
//www.genome.gov/gwastudies//JJ
)/)
./.
====================
For/IN
example/NN
,/,
we/PRP
entered/VBD
our/PRP$
top/NN
significant/JJ
SNPs/NNS
in/IN
the/DT
SNAP/NN
input/NN
panel/NN
and/CC
found/VBD
high/JJ
LD/NN
SNPs/NNS
with/IN
r2/NN
>/JJR
0.9/CD
and/CC
D/NN
'/``
=/JJ
1/CD
around/IN
1/CD
Mbp/NN
./.
====================
The/DT
high-LD/JJ
SNPs/NNS
were/VBD
investigated/VBN
in/IN
the/DT
GWAS/NN
catalog/NN
(/(
http/NN
:/:
//www.genome.gov/gwasstudies/NNS
)/)
as/IN
to/TO
whether/IN
they/PRP
were/VBD
previously/RB
reported/VBD
or/CC
not/RB
./.
====================
To/TO
maximize/VB
the/DT
candidate/NN
risk/NN
factors/NNS
of/IN
METS/NNS
,/,
we/PRP
selected/VBD
additional/JJ
functional/JJ
SNPs/NNS
in/IN
the/DT
eQTLs/NNS
or/CC
nsSNP/NN
loci/NNS
(/(
5/CD
×/NN
10-5/CD
≤/CD
p/NN
</JJR
1/CD
×/NN
10-4/CD
)/)
./.
====================
Among/IN
the/DT
Affymetrix/JJ
5.0/CD
SNPs/NNS
,/,
we/PRP
investigated/VBD
the/DT
eQTL/NN
SNPs/NNS
from/IN
regulomeDB/NN
(/(
http/NN
:/:
//regulomedb.org/JJ
)/)
and/CC
the/DT
nsSNPs/NNS
from/IN
BioMart/NN
(/(
http/NN
:/:
//www.biomart.org/JJ
)/)
./.
====================
The/DT
genetic/JJ
variances/VBZ
of/IN
the/DT
top/NN
association/NN
SNPs/NNS
were/VBD
estimated/VBN
by/IN
GCTA/NN
v1.24/CD
[/(
16/CD
]/)
,/,
which/WDT
is/VBZ
a/DT
tool/NN
for/IN
estimating/VBG
the/DT
proportion/NN
[/(
V/JJ
(/(
G/NN
)/)
/V/NN
(/(
P/NN
)/)
]/)
of/IN
phenotypic/JJ
variance/NN
[/(
V/JJ
(/(
P/NN
)/)
]/)
explained/VBN
by/IN
SNPs/NNS
[/(
V/JJ
(/(
G/NN
)/)
]/)
for/IN
complex/NN
traits/VBZ
./.
====================
We/PRP
selected/VBD
the/DT
SNP/NN
sets/NNS
based/VBN
on/IN
the/DT
GWAS/NN
p-values/NNS
from/IN
100/CD
to/TO
1,000/CD
SNPs/NNS
with/IN
10-SNP/NN
intervals/NNS
and/CC
from/IN
1,000/CD
to/TO
5,000/CD
SNPs/NNS
with/IN
1,000-SNP/NN
intervals/NNS
./.
====================
We/PRP
decided/VBD
the/DT
number/NN
of/IN
SNPs/NNS
in/IN
the/DT
maximum/NN
set/NN
based/VBN
on/IN
the/DT
genetic/JJ
variance/NN
approximated/JJ
the/DT
METS/NNS
heritability/NN
reported/VBD
from/IN
the/DT
Korean/JJ
twin/NN
study/NN
[/(
5/CD
]/)
./.
====================
The/DT
pair-wise/JJ
genetic/JJ
relationships/NNS
were/VBD
estimated/VBN
using/VBG
the/DT
make-grm/JJ
option/NN
,/,
and/CC
the/DT
proportion/NN
of/IN
the/DT
phenotypic/JJ
variance/NN
explained/VBN
by/IN
the/DT
associated/VBN
SNPs/NNS
was/VBD
estimated/VBN
by/IN
the/DT
grm-test/JJS
option/NN
with/IN
the/DT
restricted/JJ
maximum/NN
likelihood/NN
[/(
11/CD
]/)
./.
====================
In/IN
silico/NN
analysis/NN
====================
The/DT
functional/JJ
relevance/NN
of/IN
the/DT
associated/VBN
SNP/NN
sites/NNS
was/VBD
analyzed/VBN
by/IN
overlapping/VBG
the/DT
gene-coding/VBG
sequence/NN
or/CC
the/DT
Encyclopedia/NN
of/IN
DNA/NN
Element/NN
(/(
ENCODE/NN
)/)
regulatory/JJ
element/NN
positions/NNS
in/IN
the/DT
University/JJ
of/IN
California/NN
Santa/NN
Cruz/NN
(/(
UCSC/NN
)/)
genome/NN
browser/JJR
(/(
http/NN
:/:
//genome.ucsc.edu/FW
)/)
./.
====================
Thereafter/RB
,/,
regulomeDB/NN
(/(
http/NN
:/:
//regulome.stanford.edu//JJ
)/)
was/VBD
utilized/VBN
to/TO
extract/NN
eQTL/NN
information/NN
./.
====================
In/IN
addition/NN
,/,
Pathway/NN
Studio/NN
version/NN
9.0/CD
software/RB
(/(
Ariadne/NN
Genomics/NNS
,/,
Rockville/NNP
,/,
MD/NN
,/,
USA/NNP
)/)
was/VBD
utilized/VBN
to/TO
analyze/VB
the/DT
functional/JJ
interactions/NNS
and/CC
possible/JJ
pathways/NNS
among/IN
genes/proteins/NNS
in/IN
our/PRP$
data/NNS
./.
====================
It/PRP
provides/VBZ
an/DT
interpretation/NN
of/IN
the/DT
biological/JJ
implications/NNS
from/IN
gene/protein/NN
expression/NN
data/NNS
,/,
the/DT
establishment/NN
of/IN
molecular/JJ
pathways/NNS
,/,
and/CC
an/DT
identification/NN
of/IN
protein/NN
interaction/NN
maps/VBZ
and/CC
their/PRP$
association/NN
to/TO
cellular/JJ
process/NN
[/(
19/CD
]/)
./.
====================
Genome-wide/NN
association/NN
study/NN
====================
Table/JJ
1/CD
describes/VBZ
the/DT
clinical/JJ
characteristics/NNS
of/IN
Ansung/JJ
and/CC
Ansan/NN
regarding/VBG
the/DT
METS/NNS
criteria/NNS
:/:
BMI/NN
,/,
WC/NN
,/,
SBP/NN
,/,
DBP/NN
,/,
GLU0/NN
,/,
HDL/NN
,/,
and/CC
TG/NN
./.
====================
Based/VBN
on/IN
the/DT
NCEP-ATPIII/NN
METS/NNS
criteria/NNS
for/IN
Asians/JJ
[/(
14/CD
]/)
,/,
2,657/CD
KARE/NN
subjects/NNS
were/VBD
included/VBN
in/IN
the/DT
METS/NNS
cases/NNS
./.
====================
The/DT
SNPs/NNS
showing/VBG
strong/JJ
and/CC
moderate/JJ
evidence/NN
of/IN
association/NN
(/(
p/NN
</JJR
1/CD
×/NN
10-5/CD
)/)
are/VBP
indicated/VBN
in/IN
the/DT
Manhattan/JJ
plot/NN
of/IN
the/DT
GWAS/NN
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
In/IN
addition/NN
to/TO
these/DT
SNPs/NNS
,/,
we/PRP
identified/VBD
several/JJ
functional/JJ
SNPs/NNS
with/IN
suggestive/JJ
evidence/NN
of/IN
association/NN
(/(
5/CD
×/NN
10-8/CD
≤/CD
p/NN
)/)
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
selected/VBD
12/CD
SNPs/NNS
,/,
of/IN
which/WDT
2/CD
had/VBD
genome-wide/JJ
significant/JJ
associations/NNS
(/(
p/NN
</JJR
5/CD
×/NN
10-8/CD
)/)
,/,
8/CD
had/VBD
suggestive/JJ
associations/NNS
(/(
5/CD
×/NN
10-8/CD
≤/NNP
p/NN
</JJR
1/CD
×/NN
10-5/CD
)/)
,/,
and/CC
2/CD
had/VBD
functional/JJ
variants/NNS
(/(
1/LS
×/NN
10-5/CD
≤/NNP
p/NN
</JJR
1/CD
×/NN
10-4/CD
)/)
(/(
Table/JJ
2/CD
)/)
[/(
8/CD
,/,
20/CD
,/,
21/CD
,/,
22/CD
]/)
./.
====================
The/DT
top/NN
SNP/NN
(/(
rs11216126/NN
)/)
and/CC
3/CD
suggestive/JJ
SNPs/NNS
(/(
rs6589566/CD
,/,
rs174/NN
82753/CD
,/,
and/CC
rs10503669/NN
)/)
were/VBD
previously/RB
reported/VBN
as/IN
being/VBG
associated/VBN
with/IN
METS-related/JJ
traits/VBZ
,/,
such/JJ
as/IN
serum/NN
cholesterol/NN
levels/NNS
or/CC
TG/NN
levels/NNS
[/(
8/CD
,/,
20/CD
,/,
21/CD
]/)
./.
====================
LD/NN
analysis/NN
using/VBG
10/CD
SNPs/NNS
was/VBD
conducted/VBN
with/IN
the/DT
previously/RB
reported/VBD
GWAS/NN
SNPs/NNS
./.
====================
As/IN
a/DT
result/NN
,/,
5/CD
SNPs/NNS
had/VBD
strong/JJ
LD/NN
with/IN
the/DT
15/CD
highly/RB
linked/VBN
GWAS/NN
SNPs/NNS
(/(
Table/JJ
3/CD
)/)
[/(
23/CD
,/,
24/CD
,/,
25/CD
,/,
26/CD
,/,
27/CD
,/,
28/CD
,/,
29/CD
,/,
30/CD
,/,
31/CD
,/,
32/CD
,/,
33/CD
,/,
34/CD
]/)
./.
====================
Among/IN
the/DT
6/CD
remaining/VBG
SNPs/NNS
associated/VBN
with/IN
METS/NNS
in/IN
our/PRP$
GWAS/NN
results/NNS
,/,
2/CD
SNPs/NNS
(/(
rs180349/NN
and/CC
rs17410962/NN
)/)
showed/VBD
high/JJ
LD/NN
with/IN
the/DT
previously/RB
reported/VBN
SNPs/NNS
(/(
r2/NN
>/JJR
0.9/CD
and/CC
D/NN
'/``
=/JJ
1/CD
)/)
even/RB
though/IN
the/DT
2/CD
SNPs/NNS
have/VBP
not/RB
been/VBN
reported/VBN
regarding/VBG
metabolic/JJ
traits/VBZ
./.
====================
Therefore/RB
,/,
we/PRP
discovered/VBD
10/CD
significant/JJ
or/CC
suggestive/JJ
associated/VBN
SNPs/NNS
in/IN
the/DT
METS/NNS
GWAS/NN
,/,
but/CC
6/CD
of/IN
them/PRP
were/VBD
already/RB
reported/VBN
or/CC
linked/VBN
to/TO
the/DT
reported/VBN
SNPs/NNS
./.
====================
The/DT
remaining/VBG
4/CD
suggestive/JJ
signals/NNS
and/CC
2/CD
functional/JJ
variants/NNS
have/VBP
been/VBN
first/JJ
reported/VBD
in/IN
the/DT
current/JJ
study/NN
,/,
and/CC
a/DT
replication/NN
study/NN
should/MD
be/VB
performed/VBN
in/IN
other/JJ
independent/JJ
populations/NNS
./.
====================
In/IN
silico/NN
annotation/NN
of/IN
the/DT
linked/VBN
genes/NNS
and/CC
functional/JJ
relevance/NN
====================
The/DT
10/CD
associated/VBN
SNPs/NNS
and/CC
the/DT
LD/NN
SNPs/NNS
were/VBD
located/JJ
in/IN
six/CD
functional/JJ
gene/NN
regions/NNS
,/,
and/CC
one/CD
SNP/NN
was/VBD
located/JJ
in/IN
the/DT
intergenic/JJ
region/NN
./.
====================
The/DT
top/NN
signals/NNS
were/VBD
located/JJ
downstream/RB
of/IN
a/DT
functional/JJ
spliceosome-associated/VBN
protein/NN
,/,
named/VBN
BUD13/NN
,/,
a/DT
homolog/NN
of/IN
yeast/NN
(/(
BUD13/NN
)/)
gene/NN
chromosome/NN
11/CD
and/CC
near/JJ
the/DT
BUD13/NN
gene/NN
./.
====================
BUD13/NN
has/VBZ
been/VBN
reported/VBN
to/TO
be/VB
associated/VBN
with/IN
lipid/NN
,/,
metabolic/JJ
syndrome/NN
X/NN
[/(
23/CD
]/)
,/,
TG/NN
[/(
32/CD
]/)
,/,
and/CC
metabolic/JJ
traits/VBZ
in/IN
East/JJ
Asians/NNS
[/(
8/CD
]/)
,/,
demonstrating/VBG
that/IN
it/PRP
is/VBZ
putatively/RB
functionally/RB
associated/VBN
with/IN
METS/NNS
in/IN
the/DT
Korean/JJ
population/NN
(/(
Supplementary/JJ
Table/JJ
1/CD
)/)
./.
====================
The/DT
second/JJ
significant/JJ
SNP/NN
was/VBD
rs6589566/CD
,/,
which/WDT
has/VBZ
6/CD
high-LD/JJ
SNPs/NNS
./.
====================
Notably/RB
,/,
in/IN
silico/JJ
annotation/NN
of/IN
the/DT
SNP/NN
's/POS
function/NN
showed/VBD
that/IN
rs651821/NN
was/VBD
located/JJ
in/IN
the/DT
5/CD
'/``
untranslated/JJ
region/NN
(/(
UTR/NN
)/)
of/IN
the/DT
APOA5/NN
gene/NN
,/,
and/CC
also/RB
,/,
the/DT
SNP/NN
was/VBD
reported/VBN
as/IN
an/DT
eQTL/NN
of/IN
the/DT
transgelin/NN
(/(
TAGLN/NN
)/)
gene/NN
(/(
Table/JJ
4/CD
)/)
./.
====================
The/DT
results/NNS
indicate/VBP
that/IN
the/DT
remaining/VBG
SNPs/NNS
are/VBP
surrogate/NN
markers/NNS
of/IN
rs6589566/NN
./.
====================
Among/IN
them/PRP
,/,
rs651821/NN
and/CC
rs964184/NN
are/VBP
associated/VBN
with/IN
TG/NN
level/NN
,/,
as/IN
one/CD
component/NN
of/IN
METS/NNS
evaluation/NN
,/,
in/IN
Chinese/JJ
populations/NNS
[/(
26/CD
]/)
and/CC
in/IN
Mexicans/NNS
[/(
35/CD
]/)
./.
====================
Both/DT
SNPs/NNS
exhibit/VBP
eQTL/NN
of/IN
the/DT
TAGLN/NN
gene/NN
./.
====================
TAGLN/NN
has/VBZ
been/VBN
documented/VBN
as/IN
a/DT
repressive/JJ
regulator/NN
of/IN
matrix/NN
metalloproteinase/NN
9/CD
(/(
MMP9/NN
)/)
gene/NN
expression/NN
[/(
36/CD
]/)
and/CC
is/VBZ
considered/VBN
a/DT
putative/JJ
tumor/NN
suppressor/NN
due/JJ
to/TO
suppression/NN
of/IN
MMP-9/NN
,/,
which/WDT
harbors/VBZ
tumor/NN
metastatic/JJ
properties/NNS
[/(
37/CD
]/)
./.
====================
However/RB
,/,
MMP-9/NN
is/VBZ
also/RB
involved/VBN
in/IN
the/DT
progression/NN
of/IN
METS/NNS
via/IN
chymase/JJ
activity/NN
[/(
38/CD
]/)
and/CC
has/VBZ
been/VBN
suggested/VBN
to/TO
be/VB
used/VBN
a/DT
diagnostic/JJ
marker/NN
of/IN
METS/NNS
[/(
39/CD
]/)
./.
====================
Thus/RB
,/,
it/PRP
can/MD
be/VB
explained/VBN
that/DT
the/DT
functional/JJ
eQTL/NN
TAGLN/NN
of/IN
rs651821/NN
and/CC
rs964184/NN
could/MD
be/VB
a/DT
novel/JJ
marker/NN
for/IN
the/DT
evaluation/NN
of/IN
METS/NNS
in/IN
terms/NNS
of/IN
strong/JJ
regulation/NN
of/IN
MMP-9/NN
./.
====================
The/DT
third/JJ
most/JJS
significant/JJ
signals/NNS
were/VBD
located/JJ
in/IN
the/DT
lipoprotein/NN
lipase/NN
(/(
LPL/NN
)/)
gene/NN
region/NN
./.
====================
Three/CD
SNPs/NNS
(/(
rs10503669/NN
,/,
rs17482753/NN
,/,
and/CC
rs17410962/NN
)/)
located/JJ
in/IN
chr/NN
8/CD
were/VBD
eQTL/NN
that/DT
contributed/VBD
to/TO
LPL/NN
expression/NN
in/IN
monocytes/NNS
./.
====================
LPL/NN
is/VBZ
a/DT
critical/JJ
protein/NN
of/IN
lipid/NN
metabolism/NN
and/CC
is/VBZ
significantly/RB
associated/VBN
with/IN
METS/NNS
in/IN
Asian/JJ
Indians/NNS
[/(
40/CD
]/)
,/,
indicating/VBG
that/IN
the/DT
functional/JJ
eQTL-SNP/NN
of/IN
LPL/NN
expression/NN
could/MD
be/VB
a/DT
marker/NN
for/IN
the/DT
evaluation/NN
of/IN
METS/NNS
in/IN
Korean/JJ
populations/NNS
./.
====================
Those/DT
three/CD
SNPs/NNS
were/VBD
in/IN
strong/JJ
LD/NN
with/IN
rs328/NN
,/,
which/WDT
is/VBZ
a/DT
stop-gain/JJ
mutation/NN
of/IN
the/DT
LPL/NN
coding/VBG
sequence/NN
[/(
41/CD
]/)
(/(
Supplementary/JJ
Table/JJ
1/CD
)/)
./.
====================
Although/IN
the/DT
remaining/VBG
14/CD
SNPs/NNS
were/VBD
non-eQTL-SNPs/NNS
,/,
those/DT
SNPs/NNS
have/VBP
been/VBN
reported/VBN
as/IN
being/VBG
in/IN
association/NN
with/IN
HDL/NN
cholesterol/NN
,/,
low-density/JJ
lipoprotein/NN
cholesterol/NN
,/,
TG/NN
,/,
and/CC
obesity/NN
,/,
indicating/VBG
that/IN
they/PRP
are/VBP
putative/JJ
candidate/NN
markers/NNS
for/IN
the/DT
evaluation/NN
of/IN
METS/NNS
./.
====================
Although/IN
the/DT
remaining/VBG
6/CD
SNPs/NNS
and/CC
their/PRP$
nearest/JJ
genes/NNS
have/VBP
not/RB
been/VBN
functionally/RB
studied/VBN
regarding/VBG
METS-associated/JJ
traits/VBZ
,/,
further/RB
studies/NNS
are/VBP
required/VBN
to/TO
elucidate/VB
for/IN
their/PRP$
role/NN
in/IN
METS/NNS
./.
====================
Pathway/NN
network/NN
analysis/NN
====================
The/DT
results/NNS
of/IN
the/DT
V/JJ
(/(
G/NN
)/)
/V/NN
(/(
P/NN
)/)
for/IN
100/CD
to/TO
5,000/CD
SNPs/NNS
were/VBD
plotted/VBN
in/IN
Fig/NN
./.
====================
2/CD
./.
====================
When/WRB
we/PRP
used/VBD
5,000/CD
SNPs/NNS
,/,
V/JJ
(/(
G/NN
)/)
/V/NN
(/(
P/NN
)/)
approximated/VBD
50/CD
%/NN
,/,
and/CC
we/PRP
extracted/VBD
functional/JJ
SNPs/NNS
,/,
such/JJ
as/IN
eQTLs/NNS
and/CC
nsSNPs/NNS
,/,
from/IN
the/DT
5,000/CD
SNPs/NNS
./.
====================
We/PRP
could/MD
extract/VB
159/CD
eQTLs/NNS
and/CC
18/CD
nsSNPs/NNS
among/IN
the/DT
5,000/CD
SNPs/NNS
(/(
Supplementary/JJ
Table/JJ
2/CD
)/)
./.
====================
Notably/RB
,/,
6/CD
eQTL/NN
genes/NNS
and/CC
2/CD
nsSNP/NN
genes/NNS
consisted/VBD
of/IN
LPL/NN
and/CC
the/DT
apolipoprotein/NN
A-V/JJ
(/(
APOA5/NN
)/)
pathway/NN
through/IN
the/DT
interaction/NN
of/IN
a/DT
number/NN
of/IN
mediated/JJ
genes/NNS
(/(
Table/JJ
4/CD
)/)
./.
====================
Among/IN
them/PRP
,/,
muscle/NN
creatinine/NN
kinase/NN
(/(
CKM/NN
)/)
has/VBZ
been/VBN
documented/VBN
to/TO
regulate/VB
LPL/NN
activity/NN
[/(
42/CD
]/)
,/,
demonstrating/VBG
that/IN
it/PRP
is/VBZ
putatively/RB
associated/VBN
with/IN
METS/NNS
./.
====================
Those/DT
additionally/RB
identified/VBN
genes/NNS
might/MD
be/VB
candidate/NN
targets/NNS
of/IN
METS/NNS
for/IN
further/JJ
study/NN
(/(
Fig/NN
./.
====================
3/CD
)/)
./.
====================
eQTLs/NNS
and/CC
nsSNPs/NNS
provide/VBP
insights/NNS
into/IN
the/DT
regulation/NN
of/IN
transcription/NN
and/CC
aid/VB
in/IN
the/DT
interpretation/NN
of/IN
GWASs/NNS
[/(
22/CD
]/)
./.
====================
Most/JJS
of/IN
the/DT
eQTL/NN
resources/VBZ
are/VBP
available/JJ
in/IN
online/JJ
databases/NNS
,/,
such/JJ
as/IN
RegulomeDB/NN
(/(
http/NN
:/:
//regulome.stanford.edu//JJ
)/)
,/,
including/VBG
several/JJ
published/VBN
resources/VBZ
in/IN
various/JJ
cell/NN
types/NNS
,/,
such/JJ
as/IN
monocytes/NNS
[/(
43/CD
]/)
,/,
human/JJ
brain/NN
[/(
44/CD
]/)
,/,
lymphoblastoid/JJ
cell/NN
lines/NNS
[/(
45/CD
,/,
46/CD
]/)
,/,
and/CC
human/JJ
liver/NN
[/(
47/CD
]/)
./.
====================
Probably/RB
,/,
RegulomeDB/NN
is/VBZ
one/CD
of/IN
the/DT
most/JJS
useful/JJ
eQTL/NN
databases/NNS
,/,
because/IN
it/PRP
contains/VBZ
rich/JJ
information/NN
about/IN
the/DT
products/NNS
of/IN
the/DT
ENCODE/NN
project/VB
,/,
such/JJ
as/IN
transcription/NN
factor/NN
binding/NN
sites/NNS
,/,
chromatin/NN
structure/NN
,/,
histone/NN
modification/NN
,/,
and/CC
eQTLs/NNS
./.
====================
Our/PRP$
pathway/NN
results/NNS
suggest/VBP
an/DT
internal/JJ
mechanism/NN
of/IN
LPL/NN
,/,
APOA5/NN
,/,
and/CC
muscarinic/JJ
acetylcholine/NN
receptor/NN
M2/NN
(/(
CHRM2/NN
)/)
functions/VBZ
in/IN
METS/NNS
./.
====================
Therefore/RB
,/,
we/PRP
suggest/VBP
that/IN
6/CD
eQTLs/NNS
and/CC
2/CD
nsSNP/NN
loci/NNS
might/MD
be/VB
additional/JJ
targets/NNS
for/IN
further/JJ
association/NN
studies/NNS
and/CC
functional/JJ
analysis/NN
./.
====================
Conclusively/RB
,/,
our/PRP$
approach/NN
using/VBG
the/DT
conventional/JJ
GWAS/NN
,/,
reconsidering/VBG
functional/JJ
variants/NNS
and/CC
the/DT
pathway-based/JJ
interpretation/NN
,/,
suggests/VBZ
a/DT
useful/JJ
method/NN
to/TO
understand/VB
the/DT
GWAS/NN
results/NNS
of/IN
complex/NN
traits/VBZ
and/CC
can/MD
be/VB
expanded/VBN
in/IN
other/JJ
GWASs/NNS
./.
====================
Manhattan/JJ
plot/NN
of/IN
metabolic/JJ
syndrome/NN
genome-wide/NN
association/NN
study/NN
-log10/CD
(/(
p-values/NNS
)/)
./.
====================
All/DT
black/JJ
and/CC
grey/JJ
circles/NNS
indicate/VBP
the/DT
individual/JJ
single/JJ
nucleotide/NN
polymorphisms/NNS
(/(
SNPs/NNS
)/)
./.
====================
The/DT
red/JJ
horizontal/JJ
line/NN
is/VBZ
the/DT
genome-wide/NN
significance/NN
level/NN
(/(
p/NN
=/JJ
5/CD
×/NN
10-8/CD
)/)
,/,
and/CC
the/DT
blue/JJ
horizontal/JJ
line/NN
is/VBZ
the/DT
genome-wide/NN
suggestive/JJ
level/NN
(/(
5/CD
×/NN
10-8/CD
≤/CD
p/NN
</JJR
1/CD
×/NN
10-5/CD
)/)
./.
====================
The/DT
top/NN
significant/JJ
SNPs/NNS
are/VBP
depicted/VBN
on/IN
the/DT
right/JJ
site/NN
of/IN
the/DT
SNP/NN
./.
====================
The/DT
proportion/NN
of/IN
phenotypic/JJ
variance/NN
[/(
V/JJ
(/(
P/NN
)/)
]/)
explained/VBN
by/IN
the/DT
genotypic/JJ
variance/NN
[/(
V/JJ
(/(
G/NN
)/)
]/)
./.
====================
The/DT
horizontal/JJ
axis/NN
denotes/VBZ
the/DT
number/NN
of/IN
single/JJ
nucleotide/NN
polymorphisms/NNS
(/(
SNPs/NNS
)/)
./.
====================
Approximately/RB
50/CD
%/NN
of/IN
phenotypic/JJ
variance/NN
could/MD
be/VB
explained/VBN
by/IN
the/DT
top/NN
5,000/CD
SNPs/NNS
./.
====================
Illustration/NN
of/IN
molecular/JJ
pathway/NN
for/IN
significantly/RB
associated/VBN
single/JJ
nucleotide/NN
polymorphism/NN
(/(
SNP/NN
)/)
loci/NNS
in/IN
the/DT
metabolic/JJ
syndrome/NN
genome-wide/NN
association/NN
study/NN
(/(
GWAS/NN
)/)
./.
====================
The/DT
molecules/NNS
depicted/VBD
by/IN
the/DT
significant/JJ
GWAS/NN
loci/NNS
(/(
reds/VBZ
)/)
,/,
functional/JJ
SNPs/NNS
(/(
expression/NN
quantitative/JJ
trait/NN
loci/NNS
or/CC
nonsynonymous/JJ
SNPs/NNS
)/)
loci/NNS
(/(
green/CD
)/)
,/,
and/CC
the/DT
other/JJ
intermediate/JJ
molecules/NNS
(/(
yellow/RB
)/)
are/VBP
illustrated/VBN
on/IN
the/DT
cell/NN
organelles/NNS
./.
====================
Clinical/JJ
characteristics/NNS
of/IN
metabolic/JJ
syndrome-related/JJ
traits/VBZ
====================
Genome-wide/NN
association/NN
results/NNS
for/IN
METs/NNS
case-control/JJ
study/NN
in/IN
the/DT
Korean/JJ
population/NN
====================
Reported/VBN
GWAS/NN
SNPs/NNS
that/DT
show/VBP
LD/NN
with/IN
our/PRP$
study/NN
SNPs/NNS
====================
GWAS/NN
results/NNS
of/IN
eQTLs/NNS
and/CC
nonsynonymous/JJ
SNPs/NNS
consisting/VBG
of/IN
the/DT
LPL/NN
and/CC
APOA5/NN
pathways/NNS
====================
